▼ 0.23%
prev close
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2024-09-04 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 684d ago | — | |
| 2023-01-31 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 1254d ago | — |
2024-09-04
John James
ICLR
Amount
$1,001 - $15,000
Filed
684d ago
2023-01-31
Kevin Hern
ICLR
Amount
$1,001 - $15,000
Filed
1254d ago
Recent News
Powered by Polygon.io
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm
Why Icon Stock Crushed it on Wednesday
Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Trade Timeline
Congressional activity, newest first
John James
2024-09-04 · Sale
$1,001 - $15,000
Kevin Hern
2023-01-31 · Sale
$1,001 - $15,000